...
首页> 外文期刊>Journal of Neuropathology and Experimental Neurology: Official Journal of the American Association of Neuropathologists, Inc >Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
【24h】

Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.

机译:少突胶质细胞肿瘤经常表现出CDKN2A(MTS1,p16INK4a),p14ARF和CDKN2B(MTS2,p15INK4b)抑癌基因的高度甲基化。

获取原文
获取原文并翻译 | 示例

摘要

We investigated 34 oligodendroglial tumors (7 oligodendrogliomas, 11 anaplastic oligodendrogliomas, 8 oligoastrocytomas, and 8 anaplastic oligoastrocytomas) for deletion, mutation, hypermethylation, and expression of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes at 9p21. One anaplastic oligoastrocytoma carried a homozygous deletion including all 3 genes. None of the tumors demonstrated point mutations in any of the genes. Methylation-specific polymerase chain reaction (MSP) analysis and sequencing of bisulfite-modified DNA, however, revealed frequent hypermethylation of the 5'-CpG islands in CDKN2A, p14ARF, and CDKN2B. Partial or complete methylation of the majority of CpG sites analyzed from each gene was detected in 32% of the tumors at the CDKN2A gene and at a similar percentage (41%) of the tumors at the p14ARF gene and the CDKN2B gene. Most tumors with CDKN2A, p14ARF, and/or CDKN2B hypermethylation either lacked detectable transcripts from these genes or had lower mRNA levels than those determined for non-neoplastic brain tissue. There was a significant correlation between hypermethylation of these genes and the presence of allelic losses on chromosomal arms 1p and 19q. In addition, p14ARF hypermethylation was predominantly found in tumors without a demonstrated TP53 mutation. Taken together, our results indicate that hypermethylation of CDKN2A, p14ARF, and CDKN2B is an important epigenetic mechanism by which oligodendroglial tumors may escape from p53- and pRb-dependent growth control.
机译:我们调查了CDKN2A(MTS1,p16INK4a),p14ARF和TSK2b15的表达,缺失,突变,高甲基化和表达,研究了34例少突神经胶质瘤(7例少突神经胶质瘤,11例间变性少突神经胶质瘤,8例少突星形细胞瘤和8例少突细胞星形胶质瘤)。 9p21基因。一种间变性少星形细胞瘤携带纯合缺失,包括所有3个基因。没有一个肿瘤显示出任何基因的点突变。然而,亚硫酸氢盐修饰的DNA的甲基化特异性聚合酶链反应(MSP)分析和测序表明,CDKN2A,p14ARF和CDKN2B中的5'-CpG岛经常发生超甲基化。从每个基因分析的大多数CpG位点的部分或完全甲基化在CDKN2A基因的32%的肿瘤中以及在p14ARF基因和CDKN2B基因的肿瘤的相似百分比(41%)中被检测到。大多数具有CDKN2A,p14ARF和/或CDKN2B甲基化程度高的肿瘤,要么缺少这些基因的可检测转录本,要么具有比非肿瘤性脑组织确定的更低的mRNA水平。这些基因的超甲基化与染色体臂1p和19q上等位基因缺失的存在之间存在显着相关性。此外,p14ARF高甲基化主要发现于无TP53突变的肿瘤中。综上所述,我们的结果表明CDKN2A,p14ARF和CDKN2B的高度甲基化是重要的表观遗传机制,通过该机制少突胶质细胞瘤可摆脱p53和pRb依赖性生长控制。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号